Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Byoung Chul Cho; Weimin Li; Alexander I. Spira; Maxwell Sauder; Jill Feldman; Farastuk Bozorgmehr; Milena Perez Mak; Janellen Smith; Pei Jye Voon; Baogang Liu; Panwen Tian; Jiunn-Liang Tan; Cheng‐Ta Yang; Jin‐Yuan Shih; Nuri Karadurmuş; J. Cundom; Glaucio Bertollo; İrfan Çiçin; Jorge J. Nieva; Ana Laura Ortega Granados; Pascale Tomasini; Danny Nguyen; Enriqueta Felip; Julia Schuchard; Seán Murphy; Bruce G. Anderson; Tonatiuh Romero; Yichuan Xia; Shubin Sheng; Joshua Bauml; Parthiv J. Mahadevia; Juinn Huar Kam; Mehregan Nematian‐Samani; Jorge Simões; Mark Wildgust; Nicolas Girard

doi:10.1016/j.jtho.2025.07.117

Abstract

This is the authors' abstract. We don't add key points for this paper.

An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cho et al. (2025) studied this question.

synapsesocial.com/papers/69d76c03ef4aa71f97f314b5 https://doi.org/10.1016/j.jtho.2025.07.117

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Abstract

Discussion

Cite This Study

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading